Mexico / Prospects for Healthcare Ahead of 2024 Election
Mexican voters will be heading to the polls next June for what will be the largest election process in the country’s history with concurrent state and federal elections. The election will…
Landsteiner Scientific is a Mexican pharmaceutical company founded in 1998 dedicated to research, development, manufacturing, distribution and marketing of health products. The company employs 1,000 people and covers domestic as well as international markets through several business lines, encompassing prescription drugs, generics, biotech products, high specialty and in-store brands. The product portfolio contains over 70 products in 300 different presentations divided among 17 therapeutic areas. In 2013 the company entered the field of genomic medicine with the acquisition of Neopharm Obesity, a company based in Seville, Spain.
Contact details
Landsteiner Scientific
Av. Periférico Sur no. 4118, Piso 6
Col. Jardines de Pedregal
CP 01900, México DF
MEXICO
Tel: +52 (55) 5449 3690
Website: www.landsteiner.com
Mexican voters will be heading to the polls next June for what will be the largest election process in the country’s history with concurrent state and federal elections. The election will…
The latest from Mexican pharma, including the distribution agreement between Dow and Azelis, Neuraxpharm’s new LatAm subsidiaries in Mexico and Brazil; Landsteiner Scientific’s restructure, and Merck’s plant expansion in Naucalpan.…
Latin America’s patient organisations are today playing a more important role than ever before in developing solutions to the continent’s most pressing healthcare challenges. Given the healthcare gaps that persist,…
Back in Latin America after several years in the US and Europe, Teva LatAm Head and Mexico GM Rodrigo Fernandez explains how the affiliate has adapted its strategy across the…
Mexico, with the second largest pharmaceutical market in Latin America, has a number of strong local pharma industry players. These companies, no longer focused solely on the domestic market, are…
María del Socorro España Lomelí, the executive director of Mexico’s National Association of Manufacturers of Medicines (ANAFAM), speaks to PharmaBoardroom about ANAFAM’s evolving relationship with the Mexican government and the…
Dagoberto Cortés Cervantes, president of Mexico’s National Association of Medicines Manufacturers (ANAFAM) and director of Grupo Sanfer/Hormona Mexico, outlines the expansion strategy that has led the manufacturing group to extend…
The Mexican Association of Pharmaceutical Research Industries (AMIIF) represents the innovative pharmaceutical industry in Mexico, advocating for innovation and promoting dialogue with local authorities. AMIIF’s Executive Director, Cristobal Thompson, discusses…
Latin America (LatAm) Area Lead for Astellas Sandra Ramirez outlines the Japanese company’s presence in the region, its efforts to partner with local stakeholders to improve patient access, and the…
Mexico’s pharma market, the second largest in Latin America and among the top 15 globally, is set to top USD 13 billion in sales by 2028. Despite the encouraging numbers,…
The director of Mexican pharmaceutical industry association CANIFARMA, Rafael Gual Cosío, speaks out about the current contradictions plaguing Mexico’s pharma sector. Gual Cosío highlights the fact that market growth and…
The latest from Latin American pharma, including Moderna’s push to build a regional presence and partnership network; Pfizer’s health equity challenges in the region; and Brazil’s local manufacturing of AstraZeneca’s…
See our Cookie Privacy Policy Here
